CELATOR Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CELATOR, and when can generic versions of CELATOR drugs launch?
CELATOR has one approved drug.
There are nine US patents protecting CELATOR drugs.
There are one hundred and twenty-seven patent family members on CELATOR drugs in twenty-six countries and thirty-six supplementary protection certificates in sixteen countries.
Drugs and US Patents for CELATOR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 10,835,492 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 8,431,806 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 8,022,279 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 10,166,184 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CELATOR Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 03028697 | ⤷ Try a Trial |
China | 108853031 | ⤷ Try a Trial |
Japan | 6592556 | ⤷ Try a Trial |
Hong Kong | 1253378 | ⤷ Try a Trial |
Japan | 2005508921 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for CELATOR Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1744764 | 2018C/045 | Belgium | ⤷ Try a Trial | PRODUCT NAME: VYXEOS (DAUNORUBICINE/CYTARABINE); AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180823 |
2768484 | CR 2019 00051 | Denmark | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION AF DAUNORUBICIN OG CYTARABIN; REG. NO/DATE: EU/1/18/1308 20180827 |
3300601 | 27/2022 | Austria | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION VON DAUNORUBICIN UND CYTARABIN; REGISTRATION NO/DATE: EU/1/18/1308 (MITTEILUNG) 20180827 |
1744764 | 18C1047 | France | ⤷ Try a Trial | PRODUCT NAME: DAUNORUBICINE + CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
2768484 | C201930069 | Spain | ⤷ Try a Trial | PRODUCT NAME: COMBINACION DE DAUNORUBICINA Y CITARABINA; NATIONAL AUTHORISATION NUMBER: EU/1/18/1308; DATE OF AUTHORISATION: 20180823; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1308; DATE OF FIRST AUTHORISATION IN EEA: 20180823 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.